SCHEMBL1665407

SCHEMBL1665407

C=C[C@@H](N)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3348437 1.00
SCHEMBL1663118 1.00
Hydrochloric Acid SCHEMBL1367613 0.97
Hydrochloric Acid SCHEMBL15561473 0.97
Hydrochloric Acid SCHEMBL2979638 0.97
Phosphoric Acid SCHEMBL9116729 0.87 SLC6A2 (0.41)
SCHEMBL6061965 0.75
SCHEMBL3975809 0.75
Hydrochloric Acid SCHEMBL10667290 0.73
SCHEMBL6576182 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4737470-A2 C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF Zikani Therapeutics, Inc. (US) 2026-05-06 EP disclosed
US-12552825-B2 C10-alkylene substituted 13-membered macrolides and uses thereof Zikani Therapeutics , Inc. (US) 2026-02-17 US disclosed
EP-3883647-B1 C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF ZIKANI THERAPEUTICS INC (US) 2026-02-11 EP disclosed
US-20260035402-A1 C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF ZIKANI THERAPEUTICS INC (US) 2026-02-05 US disclosed
US-20250188089-A1 SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2025-06-12 US disclosed
US-12187734-B2 Substituted pyridotriazine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2025-01-07 US disclosed
EP-4196479-B9 SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES INC (US) 2024-10-16 EP disclosed
US-20240300966-A1 SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2024-09-12 US disclosed
EP-4321217-A2 SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF Gilead Sciences, Inc. (US) 2024-02-14 EP disclosed
US-11897892-B2 Substituted pyridotriazine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-13 US disclosed
EP-2038272-A2 PYRIDINONYL PDK1 INHIBITORS Sunesis Pharmaceuticals, Inc. (US) 2009-03-25 EP disclosed
WO-2008005457-A2 PYRIDINONYL PDK1 INHIBITORS SUNESIS PHARMACEUTICALS (US) 2008-01-10 WO disclosed
US-20070259965-A1 Acyclic 1,3-Diamine And Uses Therefor SMITHKLINE BEECHAM CORPORATION 2007-11-08 US disclosed
US-20070259965-A1 Acyclic 1,3-Diamine And Uses Therefor SMITHKLINE BEECHAM CORPORATION 2007-11-08 US disclosed
US-20070259965-A1 Acyclic 1,3-Diamine And Uses Therefor SMITHKLINE BEECHAM CORPORATION 2007-11-08 US disclosed
US-7173059-B2 Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same AGOURON PHARMACEUTICALS, INC. (US) 2007-02-06 US disclosed
EP-1633704-A2 INTERMEDIATES USEFUL IN THE SYNTHESIS OF HIV-PROTEASE INHIBITORS AND METHODS FOR PREPARING THE SAME PFIZER INC. (US) 2006-03-15 EP disclosed
US-20050250949-A1 Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same AGOURON PHARMACEUTICALS INC. 2005-11-10 US disclosed
WO-2004099129-A2 INTERMEDIATES USEFUL IN THE SYNTHESIS OF HIV-PROTEASE INHIBITORS AND METHODS FOR PREPARING THE SAME PFIZER INC. (US) 2004-11-18 WO disclosed
US-5068412-A Nervous system disorders such as treatment of epilepsy or Huntington's chorea SUNTORY LIMITED (JP) 1991-11-26 US disclosed